CY1114681T1 - Παραγωγο εστερα του αμινοφωσφορικου οξεος και τροποποιητης του υποδοχεα της 1-φωσφορικης σφιγγοσινης που το περιεχει ως δραστικο συστατικο - Google Patents
Παραγωγο εστερα του αμινοφωσφορικου οξεος και τροποποιητης του υποδοχεα της 1-φωσφορικης σφιγγοσινης που το περιεχει ως δραστικο συστατικοInfo
- Publication number
- CY1114681T1 CY1114681T1 CY20131101071T CY131101071T CY1114681T1 CY 1114681 T1 CY1114681 T1 CY 1114681T1 CY 20131101071 T CY20131101071 T CY 20131101071T CY 131101071 T CY131101071 T CY 131101071T CY 1114681 T1 CY1114681 T1 CY 1114681T1
- Authority
- CY
- Cyprus
- Prior art keywords
- aminosphoric
- carpine
- modifier
- phosphoric
- acid
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003607 modifier Substances 0.000 title 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 3
- 230000000051 modifying effect Effects 0.000 abstract 3
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 abstract 3
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical class NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 abstract 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
Abstract
Για την παροχή ενός αμινο φωσφορικού παραγώγου που έχει μία εξαιρετική τροποποιητική δράση στον υποδοχέα της 1-φωσφορικής σφιγγοσίνης (S1Ρ). Ως αποτέλεσμα της συνεχιζόμενης εντατικής έρευνας για τη δημιουργία μιας εξαιρετικά ασφαλούς ένωσης η οποία έχει τροποποιητική δράση στον υποδοχέα της 1-φωσφορικής σφιγγοσίνης, ανακαλύφθηκε ότι ένα αμινο φωσφορικό παράγωγο που αντιπροσωπεύεται από τον ακόλουθο γενικό τύπο (1), έχει ισχυρή τροποποιητική δράση στον υποδοχέα της S1P.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006215280 | 2006-08-08 | ||
| EP07792066.8A EP2058317B1 (en) | 2006-08-08 | 2007-08-07 | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114681T1 true CY1114681T1 (el) | 2016-10-05 |
Family
ID=39032957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131101071T CY1114681T1 (el) | 2006-08-08 | 2013-11-28 | Παραγωγο εστερα του αμινοφωσφορικου οξεος και τροποποιητης του υποδοχεα της 1-φωσφορικης σφιγγοσινης που το περιεχει ως δραστικο συστατικο |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8232319B2 (el) |
| EP (1) | EP2058317B1 (el) |
| JP (1) | JP5188972B2 (el) |
| KR (1) | KR101339976B1 (el) |
| CN (1) | CN101501049B (el) |
| CA (1) | CA2659598A1 (el) |
| CY (1) | CY1114681T1 (el) |
| DK (1) | DK2058317T3 (el) |
| ES (1) | ES2438265T3 (el) |
| HR (1) | HRP20131172T1 (el) |
| IL (1) | IL196275A (el) |
| MA (1) | MA30663B1 (el) |
| ME (1) | ME02095B (el) |
| MX (1) | MX2009001456A (el) |
| MY (1) | MY152176A (el) |
| NO (1) | NO20090606L (el) |
| NZ (1) | NZ574011A (el) |
| PL (1) | PL2058317T3 (el) |
| PT (1) | PT2058317E (el) |
| RS (1) | RS53080B (el) |
| RU (1) | RU2430925C2 (el) |
| SG (1) | SG174028A1 (el) |
| SI (1) | SI2058317T1 (el) |
| TN (1) | TNSN08545A1 (el) |
| WO (1) | WO2008018427A1 (el) |
| ZA (1) | ZA200900206B (el) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
| CA2724450A1 (en) * | 2008-05-19 | 2009-11-26 | Takeshi Tsubuki | Method for producing optically active aminoalcohol derivative |
| EP2305305A4 (en) * | 2008-05-20 | 2013-02-13 | Kyorin Seiyaku Kk | MEDIUM FOR INTRODUCTION / MAINTENANCE OF THE REMISSION |
| HRP20161133T1 (hr) | 2008-07-23 | 2016-12-02 | Arena Pharmaceuticals, Inc. | DERIVATI SUSPSTITUIRANE 1,2,3,4-TETRAHIDROCIKLOPENTA[b]INDOL-3-IL-OCTENE KISELINE KORISNI U LIJEČENJU AUTOIMUNIH I UPALNIH POREMEĆAJA |
| CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
| PT2452944E (pt) * | 2009-07-09 | 2014-10-13 | Kyorin Seiyaku Kk | Derivados de sulfureto de difenilo e medicamentos que os contêm como ingredientes activos |
| CA2786994C (en) | 2010-01-27 | 2018-01-16 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| TWI519539B (zh) | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
| AU2012245683A1 (en) * | 2011-04-18 | 2013-11-07 | Allergan, Inc. | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| CN102863345A (zh) * | 2011-07-06 | 2013-01-09 | 中国医学科学院药物研究所 | 胺基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| WO2015194157A1 (ja) * | 2014-06-16 | 2015-12-23 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体の製造方法及び製造中間体 |
| AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| HUE060485T2 (hu) | 2016-06-07 | 2023-03-28 | Tesla Inc | Villanymotor hûtési rendszer |
| JP2020507610A (ja) | 2017-02-16 | 2020-03-12 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腸管外症状を伴う炎症性腸疾患の治療のための化合物および方法 |
| KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
| US10967702B2 (en) | 2017-09-07 | 2021-04-06 | Tesla, Inc. | Optimal source electric vehicle heat pump with extreme temperature heating capability and efficient thermal preconditioning |
| AU2019280822A1 (en) | 2018-06-06 | 2021-01-07 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| EP3847158A1 (en) | 2018-09-06 | 2021-07-14 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| JP7535532B2 (ja) | 2019-02-26 | 2024-08-16 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としての縮合二環式複素環式誘導体 |
| EP4240350A4 (en) * | 2020-11-09 | 2024-09-18 | Arena Pharmaceuticals, Inc. | <sup2/>? <sub2/>?1?methods of treating conditions related to the s1preceptor |
| US11932078B2 (en) | 2021-03-31 | 2024-03-19 | Tesla, Inc. | Electric vehicle heat pump using enhanced valve unit |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444766A (en) * | 1980-10-21 | 1984-04-24 | Boehringer Mannheim Gmbh | Sulfur-containing phospholipid compounds and therapeutic compositions |
| EP0627406B1 (en) | 1992-10-21 | 1998-10-28 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| US5948820A (en) | 1994-08-22 | 1999-09-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Benzene compound and pharmaceutical use thereof |
| US5447922A (en) | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| CA2286315C (en) | 1997-04-04 | 2007-03-06 | Yoshitomi Pharmaceutical Industries Ltd. | 2-aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor |
| JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| WO2000001388A1 (en) | 1998-07-02 | 2000-01-13 | Kyowa Hakko Kogyo Co., Ltd. | Remedies for diabetes |
| AU767241B2 (en) | 1998-09-14 | 2003-11-06 | Qiang Xu | Immunosuppressive agents |
| US20020143034A1 (en) | 1998-12-30 | 2002-10-03 | Fujisawa Pharmaceutical Co. Ltd. | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists |
| AU2001264313A1 (en) | 2000-06-20 | 2002-01-02 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| NZ533997A (en) | 2000-07-13 | 2005-11-25 | Sankyo Co | Amino alcohol derivatives |
| JP2002053575A (ja) | 2000-08-09 | 2002-02-19 | Sankyo Co Ltd | アミノアルコ−ル類 |
| AU8533101A (en) | 2000-08-31 | 2002-03-13 | Merck & Co Inc | Phosphate derivatives as immunoregulatory agents |
| EP1383778B1 (en) | 2001-01-30 | 2009-10-21 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| CA2435739A1 (en) | 2001-02-22 | 2002-09-06 | Novartis Ag | Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| US7326801B2 (en) | 2001-03-26 | 2008-02-05 | Novartis Ag | 2-amino-propanol derivatives |
| JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
| US7179817B2 (en) | 2001-05-10 | 2007-02-20 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| US20040138462A1 (en) | 2001-05-24 | 2004-07-15 | Minoru Sakurai | Aminoalcohol derivatives |
| US20040235794A1 (en) | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
| ATE463478T1 (de) | 2001-09-27 | 2010-04-15 | Kyorin Seiyaku Kk | Diaryletherderivat, dessen additionssalz und immunosuppressivum |
| AU2002332289B2 (en) | 2001-09-27 | 2007-05-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| JP2005112721A (ja) | 2001-11-06 | 2005-04-28 | Maruha Corp | 含窒素化合物、製造法、及びその利用方法 |
| JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
| WO2003051876A1 (en) | 2001-12-14 | 2003-06-26 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| JP4771511B2 (ja) | 2003-07-08 | 2011-09-14 | 第一三共株式会社 | アミノアルコ−ル誘導体又はホスホン酸誘導体を含有する医薬組成物 |
| JP2003267936A (ja) | 2002-01-11 | 2003-09-25 | Sankyo Co Ltd | ベンゼン環化合物 |
| RU2330839C2 (ru) | 2002-01-11 | 2008-08-10 | Санкио Компани, Лимитед | Производные аминоспиртов или производные фосфорных кислот и фармацевтические композиции, содержащие указанные производные |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| ATE441654T1 (de) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| EP1482896A4 (en) | 2002-03-01 | 2005-11-23 | Merck & Co Inc | AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS |
| JP2005531506A (ja) | 2002-03-01 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004002531A1 (ja) | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 血管の収縮または拡張による疾患治療剤 |
| US7241790B2 (en) | 2002-07-30 | 2007-07-10 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
| AU2003273865A1 (en) | 2002-09-13 | 2004-04-30 | Novartis Ag | Amino-propanol derivatives |
| AU2003264430B2 (en) | 2002-09-19 | 2009-03-19 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| MXPA05003254A (es) | 2002-09-24 | 2005-06-08 | Novartis Ag | Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion. |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| JP4140698B2 (ja) | 2002-10-18 | 2008-08-27 | 第一三共株式会社 | リン酸又はホスホン酸誘導体 |
| JP4516430B2 (ja) | 2002-12-20 | 2010-08-04 | メルク・シャープ・エンド・ドーム・コーポレイション | １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール |
| JP4505449B2 (ja) | 2003-02-11 | 2010-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 新規二環式化合物および組成物 |
| DK1602660T3 (da) * | 2003-02-18 | 2011-05-23 | Kyorin Seiyaku Kk | Aminophosphonsyrederivater, additionssalte deraf og S1P-receptormodulatorer |
| JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ２−アミノ‐１，３‐プロパンジオール誘導体とその付加塩 |
| JP2004307439A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | アミノジオール誘導体とその付加塩及び免疫抑制剤 |
| JP2004307442A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ヘテロ環誘導体とその付加塩及び免疫抑制剤 |
| JP2004307441A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | ベンゼン誘導体とその付加塩及び免疫抑制剤 |
| ATE547395T1 (de) | 2003-04-30 | 2012-03-15 | Novartis Pharma Gmbh | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors |
| ES2392167T3 (es) | 2003-04-30 | 2012-12-05 | Novartis Ag | Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato |
| CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| CN1787817B (zh) | 2003-05-19 | 2011-09-07 | Irm责任有限公司 | 免疫抑制剂化合物及组合物 |
| WO2004113330A1 (en) | 2003-05-19 | 2004-12-29 | Irm Llc | Immunosuppressant compounds and compositions |
| GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
| JP2005047899A (ja) | 2003-07-11 | 2005-02-24 | Sankyo Co Ltd | アミノアルコール化合物 |
| WO2005014525A2 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
| WO2005014603A1 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Phosphinane compounds with immunomodulating activity |
| MXPA06002349A (es) | 2003-08-28 | 2006-05-22 | Novartis Ag | Derivados de aminopropanol. |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| GB0324210D0 (en) | 2003-10-15 | 2003-11-19 | Novartis Ag | Organic compounds |
| WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
| WO2005044780A1 (ja) | 2003-11-10 | 2005-05-19 | Kyorin Pharmaceutical Co., Ltd. | アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤 |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| TW200526548A (en) | 2003-12-25 | 2005-08-16 | Sankyo Co | Ether derivatives |
| GB0401332D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| TWI355934B (en) | 2004-02-24 | 2012-01-11 | Sankyo Co | Pharmaceutical composition for treatment or prophy |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| US7718704B2 (en) | 2004-02-24 | 2010-05-18 | Irm Llc | Immunosuppressant compounds and compositions |
| JP2005247691A (ja) | 2004-03-01 | 2005-09-15 | Toa Eiyo Ltd | Ｓ１ｐ３受容体拮抗薬 |
| GB0405289D0 (en) | 2004-03-09 | 2004-04-21 | Novartis Ag | Organic compounds |
| GB0411929D0 (en) | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| ATE502630T1 (de) | 2004-07-16 | 2011-04-15 | Kyorin Seiyaku Kk | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
| TW200611687A (en) | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
| AU2005272619A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity |
| AU2005292984B2 (en) | 2004-10-12 | 2011-01-20 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride or hydrate thereof and intermediate for the same |
| WO2006041015A1 (ja) * | 2004-10-12 | 2006-04-20 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| JP2008522977A (ja) | 2004-12-06 | 2008-07-03 | ユニバーシティ オブ バージニア パテント ファンデーション | スフィンゴシン＝１−リン酸のアリールアミドアナログ |
| TW200702326A (en) | 2005-05-31 | 2007-01-16 | Mitsubishi Pharma Corp | 2-aminobutanol compound and its pharmaceutical use |
| TWI418350B (zh) | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ｐｐａｒ調節劑之醫藥組成物的用途 |
| NZ588372A (en) | 2005-09-09 | 2012-03-30 | Novartis Ag | Diphenyl ether or thioether derivatives for treatment of autoimmune diseases |
| RU2421214C2 (ru) | 2005-10-07 | 2011-06-20 | Киорин Фармасьютикал Ко., Лтд. | Терапевтическое средство для лечения гепатита и способ лечения гепатита |
| JP5140854B2 (ja) | 2005-10-12 | 2013-02-13 | トーアエイヨー株式会社 | Ｓ１ｐ３受容体拮抗剤 |
| TWI389683B (zh) | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| JP5100641B2 (ja) | 2006-04-28 | 2012-12-19 | 田辺三菱製薬株式会社 | ２−アミノブタノール化合物及びその医薬用途 |
| BRPI0714593A2 (pt) | 2006-07-25 | 2013-05-07 | Alcon Res Ltd | antagonistas de receptores da subfamÍlia 3 (edg-3, s1p3) do gene de diferenciaÇço endotelial para a prevenÇço e tratamento de doenÇas oculares, composiÇÕes compreendendo os referidos antagonistas, e usos dos mesmos |
| US7877152B2 (en) | 2006-07-31 | 2011-01-25 | JusJas LLC | Bipolar stimulation/recording device with widely spaced electrodes |
-
2007
- 2007-08-07 US US12/310,007 patent/US8232319B2/en not_active Expired - Fee Related
- 2007-08-07 PL PL07792066T patent/PL2058317T3/pl unknown
- 2007-08-07 RS RS20130551A patent/RS53080B/sr unknown
- 2007-08-07 CN CN2007800295082A patent/CN101501049B/zh not_active Expired - Fee Related
- 2007-08-07 HR HRP20131172TT patent/HRP20131172T1/hr unknown
- 2007-08-07 NZ NZ574011A patent/NZ574011A/en not_active IP Right Cessation
- 2007-08-07 WO PCT/JP2007/065397 patent/WO2008018427A1/ja not_active Ceased
- 2007-08-07 KR KR1020097004756A patent/KR101339976B1/ko not_active Expired - Fee Related
- 2007-08-07 EP EP07792066.8A patent/EP2058317B1/en active Active
- 2007-08-07 RU RU2009106934/04A patent/RU2430925C2/ru not_active IP Right Cessation
- 2007-08-07 MX MX2009001456A patent/MX2009001456A/es active IP Right Grant
- 2007-08-07 DK DK07792066.8T patent/DK2058317T3/da active
- 2007-08-07 ME MEP-2013-551A patent/ME02095B/me unknown
- 2007-08-07 CA CA002659598A patent/CA2659598A1/en not_active Abandoned
- 2007-08-07 ES ES07792066.8T patent/ES2438265T3/es active Active
- 2007-08-07 MY MYPI20085394 patent/MY152176A/en unknown
- 2007-08-07 SG SG2011055589A patent/SG174028A1/en unknown
- 2007-08-07 JP JP2008528818A patent/JP5188972B2/ja not_active Expired - Fee Related
- 2007-08-07 SI SI200731372T patent/SI2058317T1/sl unknown
- 2007-08-07 PT PT77920668T patent/PT2058317E/pt unknown
-
2008
- 2008-12-30 IL IL196275A patent/IL196275A/en not_active IP Right Cessation
- 2008-12-31 TN TNP2008000545A patent/TNSN08545A1/en unknown
-
2009
- 2009-01-09 ZA ZA200900206A patent/ZA200900206B/xx unknown
- 2009-02-10 NO NO20090606A patent/NO20090606L/no not_active Application Discontinuation
- 2009-02-26 MA MA31663A patent/MA30663B1/fr unknown
-
2013
- 2013-11-28 CY CY20131101071T patent/CY1114681T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2058317E (pt) | Derivado de éster do ácido aminofosfórico e modulador de receptor s1p contendo o mesmo como ingrediente activo | |
| MX2021012823A (es) | Compuesto lipidico y composicion del mismo. | |
| MX2010003925A (es) | Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p). | |
| ECSP056127A (es) | Inhibidores de 3-quinasa de fosfatidil-inositol | |
| CY1113890T1 (el) | Φαρμακευτικοι συνδυασμοι που περιεχουν βενζοξαζινες για τη θεραπεια νοσων των αναπνευστικων οδων | |
| PH12014501162A1 (en) | Aryl dihydropyridinone and piperidinone as mgat2 inhibitors | |
| MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
| CY1110318T1 (el) | Παραγωγα φαινοξυοξικου οξεος | |
| NO20060847L (no) | Substituert 2-aminotetralin til behandling av depresjon | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| CY1110812T1 (el) | Παραγωγα διφαινυλοξυοξικου οξεος για τη θεραπεια αναπνευστικων διαταραχων | |
| CO6321277A2 (es) | Derivado heterociclico fusionado que tiene una actitud inhibidora de smo superior y baja toxicidad | |
| UA105229C2 (uk) | Фармацевтичний склад | |
| CY1112185T1 (el) | Σταθερο συμπλοκο δραστικων ουσιων απο αλατα των o-ακετυλοσαλικυλικων οξεων με βασικα αμινοξεα και γλυκινη | |
| CY1110034T1 (el) | Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν | |
| CY1115838T1 (el) | Μεθοδος για τη σταθεροποιηση φαρμακοτεχνικων μορφων που περιεχουν μικροοργανισμους | |
| AR074545A1 (es) | Proceso de preparacion de dihidroetorfina | |
| ATE465152T1 (de) | Verfahren zum herstellen von alkylaniliden aus halogenbenzolderivaten | |
| EA201070603A1 (ru) | Лекарственное средство, активное в отношении невропатической боли | |
| MY148732A (en) | Triazolium salts as par1 inhibitors, production thereof, and use as medicaments | |
| EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
| DE502006003194D1 (de) | Salze substituierter allophansäureester und deren verwendung in arzneimitteln | |
| MX2010006995A (es) | 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico. | |
| PH12022551271A1 (en) | Novel amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | |
| EA200600760A1 (ru) | Новые соединения фенилпиридилпиперазина, способ их получения и фармацевтические композиции, содержащие их |